Ameyaw Elvis Ofori, Koffuor George Asumeng, Asare Kwame Kumi, Konja Daniels, Du-Bois Asante, Kyei Samuel, Forkuo Arnold Donkor, Abankwah Owusu Mensah Richard Nana
Department of Biomedical Sciences, College of Health and Allied Sciences, School of Allied Health Sciences, University of Cape Coast, Cape Coast, Ghana.
Department of Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
J Intercult Ethnopharmacol. 2016 May 30;5(3):263-73. doi: 10.5455/jice.20160606124435. eCollection 2016 Jun-Aug.
Effective long-term management is the key to treatment of diabetes mellitus (DM) and its complications.
To ascertain the ability of cryptolepine (CRP) in managing DM and some associated complications.
Changes in fasting blood sugar (FBS), body weight, response to thermally-induced pain, and semen quality were assessed in normal and alloxan-induced diabetic rats treated with CRP (10, 30, or 100 mg/kg), glibenclamide (10 mg/kg), or normal saline (2 ml/kg) per os. Hematological profile, liver and kidney function tests, lipid profile, as well as liver, kidney, and pancreas histopathological examinations were also conducted to establish possible effects of CRP treatment.
CRP treatment reduced (P ≤ 0.001) FBS and body weight, inhibited (P ≤ 0.05 - 0.001) the latency to tail flick or withdrawal from pain stimulus. It did not alter (P > 0.05): Hematological parameters, elevated (P ≤ 0.05 - 0.001) plasma aspartate transaminase, alanine transaminase, and gamma-glutamyl transferase, reduced (P ≤ 0.01) plasma urea, and elevated (P ≤ 0.001) plasma creatinine associated with DM. CRP, however, reversed (P ≤ 0.05 - 0.001) DM-associated elevation (P ≤ 0.05 - 0.001) of plasma cholesterol, triglycerides, and low-density lipoproteins, and the reduction in high-density lipoproteins. CRP (10-30 mg/kg) showed dose-dependent regeneration of β-islet cells but could not repair degenerated liver and kidney tissue. CRP worsens dose-dependently (P ≤ 0.001) reduced sperm quality associated with DM.
CRP abolishes hyperglycemia, weight loss, cold allodynia, neuropathic pain, and hyperlipidemia as well as pancreatic β-islet cell damage associated with DM. It, however, does not improve liver and kidney damage and lowered semen quality.
有效的长期管理是治疗糖尿病（DM）及其并发症的关键。
确定隐丹参酮（CRP）治疗DM及一些相关并发症的能力。
对正常大鼠和用四氧嘧啶诱导的糖尿病大鼠经口给予CRP（10、30或100mg/kg）、格列本脲（10mg/kg）或生理盐水（2ml/kg），评估空腹血糖（FBS）、体重、对热诱导疼痛的反应和精液质量的变化。还进行了血液学检查、肝肾功能测试、血脂谱分析以及肝、肾和胰腺组织病理学检查，以确定CRP治疗的可能效果。
CRP治疗可降低（P≤0.001）FBS和体重，抑制（P≤0.05 - 0.001）甩尾或从疼痛刺激中撤回的潜伏期。它未改变（P>0.05）血液学参数，升高了（P≤0.05 - 0.001）血浆天冬氨酸转氨酶、丙氨酸转氨酶和γ-谷氨酰转移酶，降低了（P≤0.01）血浆尿素，并升高了（P≤0.001）与DM相关的血浆肌酐。然而，CRP可逆转（P≤0.05 - 0.001）与DM相关的血浆胆固醇、甘油三酯和低密度脂蛋白的升高以及高密度脂蛋白的降低。CRP（10 - 30mg/kg）显示出β胰岛细胞的剂量依赖性再生，但无法修复退化的肝和肾组织。CRP会使与DM相关的精子质量降低呈剂量依赖性恶化（P≤0.001）。
CRP可消除高血糖、体重减轻、冷觉异常、神经性疼痛和高脂血症以及与DM相关的胰腺β胰岛细胞损伤。然而，它并不能改善肝和肾损伤以及降低的精液质量。
